申联生物医药（上海）股份有限公司 2024 年年度股东大会会议资料 证券代码：688098 证券简称：申联生物 申联生物医药（上海）股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 目录 | 申联生物医药（上海）股份有限公司 2024 年年度股东大会会议须知 | 3 | | --- | --- | | 申联生物医药（上海）股份有限公司 2024 年年度股东大会会议议程 | 5 | | 申联生物医药（上海）股份有限公司 年年度股东大会会议议案 2024 | 7 | | 议案 1：关于公司《2024 年度董事会工作报告》的议案 | 7 | | 议案 2：关于公司《2024 年度监事会工作报告》的议案 | 13 | | 议案 3：关于公司《2024 年年度报告》及其摘要的议案 | 16 | | 议案 4：关于公司 2024 年年度利润分配方案的议案 | 17 | | 议案 5：关于公司《2024 年度财务决算报告》的议案 | 19 | | 议案 6：关于公司及子公司 2025 年度向金融机构申请综合授信额度的议案 | | | | 24 | | 议案 7：关于提请股东大会授权董事会以简易程序向特定 ...

申联生物医药（上海）股份有限公司 第四届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 申联生物医药（上海）股份有限公司（以下简称"公司"）第四届监事会第 三次会议于 2025 年 4 月 28 日以现场结合通讯方式召开，本次会议通知已于 2025 年 4 月 18 日以电子邮件方式送达公司全体监事。本次会议由监事会主席吴守常 先生主持，会议应出席监事 3 名，实际出席监事 3 名，会议的召集和召开程序符 合《中华人民共和国公司法》和《公司章程》等相关规定，会议形成的决议合法、 有效。 二、监事会会议审议情况 （一）审议通过《关于公司<2024 年度监事会工作报告>的议案》 监事会认为：2024 年度，公司监事会严格按照《中华人民共和国公司法》 《中华人民共和国证券法》《上海证券交易所科创板股票上市规则》等法律、法 规以及《公司章程》《监事会议事规则》等规定和要求，从维护公司利益及全体 股东合法权益出发，认真履行和独立行使各项监事会的监督职权和义务，积极参 与过程监督，认真 ...

证券代码：688098 证券简称：申联生物 公告编号：2025-014 申联生物医药（上海）股份有限公司 第四届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 申联生物医药（上海）股份有限公司（以下简称"公司"）第四届董事会第 三次会议于 2025 年 4 月 28 日以现场结合通讯方式召开，会议通知于 2025 年 4 月 18 日以通讯方式向全体董事发出。会议应出席的董事 9 名，实际出席的董事 9 名。本次会议的召集和召开程序符合《中华人民共和国公司法》（以下简称"《公 司法》"）和《申联生物医药（上海）股份有限公司章程》（以下简称"《公司章程》"） 等相关规定，会议形成的决议合法、有效。 二、董事会会议审议情况 1 本议案尚需提交公司股东大会审议。 （三）审议通过《关于公司<2024 年年度报告>及其摘要的议案》 董事会认为：公司《2024 年年度报告》及其摘要的编制和审议程序符合相 关法律法规和公司管理制度等相关规定，公允地反映了公司 2024 年度的财务状 况和 ...

证券代码：688098 证券简称：申联生物 公告编号：2025-017 申联生物医药（上海）股份有限公司 2024 年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 申联生物医药（上海）股份有限公司（以下简称"公司"）2024 年年度 利润分配方案为：拟不进行现金分红，不送红股，不进行资本公积转增股本和其 他形式的利润分配。 根据《上市公司股份回购规则》规定，"上市公司以现金为对价，采用要 约方式、集中竞价方式回购股份的，视同上市公司现金分红，纳入现金分红的相 关比例计算。"公司 2024 年度以集中竞价交易方式回购公司股份的金额为 18,320,763.70 元（不含交易费用），视同现金分红金额。 不触及《上海证券交易所科创板股票上市规则》第 12.9.1 条第一款第（八） 项规定的可能被实施其他风险警示的情形。 本次利润分配方案已经公司第四届董事会第三次会议审议通过，尚需提交 公司 2024 年年度股东大会审议。 一、利润分配方案内容 （一）利润分配方案的具体内容 经审计机构容诚会 ...

证券代码：688098 证券简称：申联生物 公告编号：2025-018 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 授权董事会根据《中华人民共和国公司法》《中华人民共和国证券法》 《注册管理办法》等有关法律、法规和规范性文件的规定，对公司实际情况进 行自查和论证，确认公司是否符合以简易程序向特定对象发行股票的条件。 （二）本次发行证券的种类和数量 一、本次授权事项概述 根据《上市公司证券发行注册管理办法》（以下简称"《注册管理办 法》"）《上海证券交易所上市公司证券发行上市审核规则》《上海证券交易 所上市公司证券发行与承销业务实施细则》等有关规定，申联生物医药（上 海）股份有限公司（以下简称"公司"）于2025年4月28日召开第四届董事会第 三次会议，审议通过了《关于提请股东大会授权董事会以简易程序向特定对象 发行股票并办理相关事宜的议案》，同意公司董事会提请股东大会授权董事会 向特定对象发行融资总额不超过人民币3亿元且不超过最近一年末净资产20%的 股票，授权期限为自2024年年度股东大会通过之日起至2025年年度股 ...

Financial Performance - The company's operating revenue for 2024 was CNY 30,341.47 million, a slight increase of 0.64% compared to CNY 30,148.71 million in 2023[24]. - The net profit attributable to shareholders for 2024 was CNY -4,474.01 million, representing a significant decrease of 241.95% from CNY 3,151.87 million in 2023[24]. - The net cash flow from operating activities increased dramatically to CNY 8,936.20 million, up 2,434.71% from CNY 352.55 million in 2023[24]. - The basic earnings per share for 2024 was CNY -0.11, a decrease of 237.5% from CNY 0.08 in 2023[25]. - The weighted average return on equity decreased to -3.07% in 2024, down 5.19 percentage points from 2.12% in 2023[25]. - The company achieved operating revenue of 303.41 million yuan, a year-on-year increase of 0.64%[148]. - The net profit attributable to shareholders was -44.74 million yuan, a year-on-year decrease of 241.95%[148]. - Operating costs increased by 37.16% to 120.61 million yuan compared to the previous year[149]. - Research and development expenses rose by 10.84% to 49.36 million yuan, reflecting an expansion of the R&D team[149]. - The gross margin for the main business decreased by 10.7 percentage points to 60.12%[152]. Research and Development - Research and development expenses accounted for 28.34% of operating revenue in 2024, an increase of 4.94 percentage points from 23.4% in 2023[25]. - The company invested 85.99 million yuan in R&D in 2024, with 28 national patents filed and 2 new veterinary drug registration certificates obtained[36]. - The company has established five major technology platforms: inactivated vaccine technology, synthetic peptide vaccine technology, virus-like particle vaccine technology, nucleic acid (mRNA) technology, and in vitro diagnostic technology[113]. - The company has increased R&D investment, with total R&D expenditures reaching ¥85,992,438.63, a 21.88% increase from the previous year, and R&D expenditures as a percentage of revenue rising to 28.34%[105]. - The company has applied for 28 new patents this year, including 8 invention patents, bringing the total number of patents to 146, with 85 granted[103]. - The company is focusing its R&D resources on key projects to enhance its competitive edge in disease prevention products[185]. - The company is actively working on new product launches and market expansion, but market promotion of new products has been affected by a complex market environment[136]. Product Development and Innovation - The company has developed proprietary technologies such as i-Molsta for vaccine antigen stabilization and i-Nada for efficient vaccine adjuvant technology, showcasing innovation in product development[14]. - The company is advancing the development of new vaccine projects, including circular RNA vaccines and genetically engineered subunit vaccines, to enhance its competitive edge in the market[26]. - The company is focusing on the development of multivalent vaccines and gene-engineered vaccines to reduce the number of vaccinations required for immunized animals, thereby alleviating the burden on farmers[84]. - The company has established a virus-like particle (VLP) vaccine technology platform that supports the development of multi-valent vaccines, having completed rapid construction and scale-up production technology for major categories of VLPs, including foot-and-mouth disease virus and rotavirus[96]. - The mRNA vaccine technology platform has made key progress, with the completion of core technology platforms for mRNA design and production, enabling the company to produce core raw materials independently, which is crucial for efficient vaccine development and cost control[98]. - The company is actively researching and developing new adjuvants, particularly water-based adjuvants, to enhance vaccine efficacy and safety[86]. - The company has successfully developed and optimized the process for the inactivated vaccine for bovine nodular dermatitis, which shows improved immunization effects[92]. Market and Sales Strategy - The company is focusing on large-scale breeding groups and provincial pig farms to enhance brand influence and product recognition[60]. - The company is enhancing its marketing system to focus on large-scale breeding groups, integrating marketing, R&D, and service functions to improve customer satisfaction[42]. - The company is actively expanding into the pet market, developing high-quality biological products to meet increasing demand[66]. - The company is implementing a "three-step overseas expansion model" targeting Southeast Asia, Central Asia, South America, and Africa to meet the demand for animal vaccines[46]. - The company is expanding its ruminant vaccine portfolio, with key breakthroughs in the development of vaccines for bovine viral diarrhea and ovine cysticercosis[38]. - The company is actively expanding its overseas market by leveraging advanced biopharmaceutical technology platforms and capital operation tools, focusing on human innovative drugs[46]. Governance and Compliance - The company has a standard unqualified audit report from Rongcheng Accounting Firm, ensuring the accuracy and completeness of its financial statements[6]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties, reflecting good governance practices[9]. - The company has strict compliance with GMP regulations, but potential risks exist regarding the renewal of necessary production licenses and permits[137]. - The company maintains a controllable biosecurity risk status, having passed the biosecurity level three acceptance, but must adhere to strict management to avoid potential biosecurity hazards[138]. - The company is committed to environmental protection but faces risks related to stricter national environmental standards that could impact its operations and reputation[140]. Risks and Challenges - The company has identified significant risk factors in its management discussion, which investors are advised to review carefully[5]. - The company is facing risks of significant performance decline due to intensified competition in the animal health industry, leading to decreased product prices and increased operational costs[132]. - The company faces risks related to accounts receivable collection due to reliance on government procurement and market sales[142]. - The company is at risk of losing tax benefits if it fails to maintain its status as a high-tech enterprise, which currently allows a reduced corporate income tax rate of 15%[143].

非经营性资金占用及其他关联资金 往来情况专项说明 申联生物医药（上海）股份有限公司 容诚专字[2025]100Z0661 号 容诚会计师事务所(特殊普通合伙) 中国·北京 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 关于申联生物医药（上海）股份有限公司 非经营性资金占用及其他关联资金往来情况专项说明 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 容诚专字[2025]100Z0661 号 申联生物医药（上海）股份有限公司全体股东： 我们接受委托，依据中国注册会计师审计准则审计了申联生物医药（上海）股 份有限公司（以下简称申联生物公司）2024 年 12 月 31 日的合并及母公司资产负 债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表和合并及母公 司所有者权益变动表以及财务报表附注，并于 2025 年 4 月 28 日出具了容诚审字 [2025]100Z137 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥78,741,129.63, representing a decrease of 10.58% compared to ¥88,058,162.67 in the same period last year[4]. - The net profit attributable to shareholders was -¥3,019,866.61, while the net profit after deducting non-recurring gains and losses was -¥4,450,133.90, indicating a continued loss[4]. - Net profit for Q1 2025 was a loss of ¥4,054,605.47, compared to a loss of ¥3,125,388.59 in Q1 2024, representing a 29.7% increase in loss[18]. - Basic and diluted earnings per share for Q1 2025 were both -¥0.01, unchanged from Q1 2024[19]. - Cash received from sales and services in Q1 2025 was ¥34,850,686.15, down 30.9% from ¥50,460,078.65 in Q1 2024[20]. Cash Flow - The net cash flow from operating activities was -¥28,560,955.60, compared to -¥24,404,381.56 in the same period last year, indicating a worsening cash flow situation[4]. - Cash flow from operating activities for Q1 2025 was a net outflow of ¥28,560,955.60, compared to a net outflow of ¥24,404,381.56 in Q1 2024[20]. - Net cash flow from investment activities was $15,648,403.65, a decrease from $20,450,214.15 in the previous period, reflecting a decline of approximately 23.5%[21]. - The net increase in cash and cash equivalents was -$14,827,032.87, compared to -$4,035,094.87, indicating a decline of about 267%[21]. - The ending balance of cash and cash equivalents was $96,342,060.93, down from $40,805,615.51, reflecting a decrease of approximately 136%[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,560,660,343.91, a slight increase of 0.42% from ¥1,554,117,949.14 at the end of the previous year[5]. - Total liabilities as of the end of Q1 2025 were ¥140,772,376.01, an increase from ¥128,495,487.08 at the end of Q1 2024[16]. - The company's cash and cash equivalents decreased to RMB 96,483,629.97 from RMB 146,206,489.54 in the previous period, representing a decline of approximately 34%[12]. - Accounts receivable increased to RMB 302,159,319.19, up from RMB 261,397,654.93, indicating a growth of about 15.6%[12]. - The total non-current assets reached RMB 1,018,721,546.88, slightly up from RMB 1,003,287,152.99, showing a modest increase of about 1.8%[13]. Research and Development - Research and development expenses totaled ¥14,871,393.62, which is an increase of 4.84% from ¥14,184,983.93 in the previous year, accounting for 18.89% of operating revenue, up from 16.11%[4][5]. - Research and development expenses for Q1 2025 were ¥11,111,043.54, a decrease of 12.1% from ¥12,646,826.27 in Q1 2024[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,892[8]. - The largest shareholder, Yang Yufang, holds 21.93% of the shares, totaling 90,063,197 shares[9]. - UNITED BIOMEDICAL, INC. holds 10.52% of the shares, totaling 43,199,898 shares, with a portion of shares frozen[9]. Other Information - The company continues to focus on cost control and optimizing R&D resources despite the decline in revenue[7]. - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[11].

内部控制审计报告 申联生物医药（上海）股份有限公司 容诚审字[2025]100Z1518 号 容诚会计师事务所(特殊普通合伙) 中国·北京 内部控制审计报告 容诚审字[2025]100Z1518 号 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 申联生物医药（上海）股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了申联生物医药（上海）股份有限公司（以下简称"申联生物公司"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是申联 生物公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财 ...

国信证券股份有限公司 国信证券股份有限公司（以下简称"国信证券"）作为申联生物医药（上海） 股份有限公司（以下简称"申联生物"或"公司"）首次公开发行股票并在科创 板上市持续督导的保荐机构，履行持续督导职责，并根据《上市公司监管指引第 2号——上市公司募集资金管理和使用的监管要求》及《上海证券交易所科创板 上市公司自律监管指引第1号——规范运作》等规范性法律文件的要求，对申联 生物2024年度募集资金存放与实际使用情况进行了审慎核查，核查情况及意见如 下： 一、募集资金的基本情况 （一）实际募集资金金额、资金到账时间 根据中国证券监督管理委员会（以下简称"中国证监会")作出的《关于同 意申联生物医药（上海）股份有限公司首次公开发行股票注册的批复》（证监许 可[2019]1743 号），同意公司向社会公开发行人民币普通股（A 股）5,000 万股。 公司于 2019 年 10 月 28 日完成了首次公开发行并上市工作，首次公开发行价格 为每股 8.80 元，募集资金总额为 440,000,000.00 元，扣除发行费用 39,825,000.00 元，募集资金净额 400,175,000.00 元。截止 201 ...